These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21697455)

  • 1. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.
    Yang J; Riella LV; Chock S; Liu T; Zhao X; Yuan X; Paterson AM; Watanabe T; Vanguri V; Yagita H; Azuma M; Blazar BR; Freeman GJ; Rodig SJ; Sharpe AH; Chandraker A; Sayegh MH
    J Immunol; 2011 Aug; 187(3):1113-9. PubMed ID: 21697455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection.
    Tanaka K; Albin MJ; Yuan X; Yamaura K; Habicht A; Murayama T; Grimm M; Waaga AM; Ueno T; Padera RF; Yagita H; Azuma M; Shin T; Blazar BR; Rothstein DM; Sayegh MH; Najafian N
    J Immunol; 2007 Oct; 179(8):5204-10. PubMed ID: 17911605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy.
    Yang J; Popoola J; Khandwala S; Vadivel N; Vanguri V; Yuan X; Dada S; Guleria I; Tian C; Ansari MJ; Shin T; Yagita H; Azuma M; Sayegh MH; Chandraker A
    Circulation; 2008 Feb; 117(5):660-9. PubMed ID: 18212277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.
    Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH
    J Immunol; 2005 Mar; 174(6):3408-15. PubMed ID: 15749874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD28-independent costimulation of T cells in alloimmune responses.
    Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH
    J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo.
    Yuan X; Salama AD; Dong V; Schmitt I; Najafian N; Chandraker A; Akiba H; Yagita H; Sayegh MH
    J Immunol; 2003 Mar; 170(6):2949-55. PubMed ID: 12626546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo.
    Yamada A; Salama AD; Sho M; Najafian N; Ito T; Forman JP; Kewalramani R; Sandner S; Harada H; Clarkson MR; Mandelbrot DA; Sharpe AH; Oshima H; Yagita H; Chalasani G; Lakkis FG; Auchincloss H; Sayegh MH
    J Immunol; 2005 Feb; 174(3):1357-64. PubMed ID: 15661893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism.
    Lee I; Wang L; Wells AD; Ye Q; Han R; Dorf ME; Kuziel WA; Rollins BJ; Chen L; Hancock WW
    J Immunol; 2003 Dec; 171(12):6929-35. PubMed ID: 14662900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts.
    Riella LV; Watanabe T; Sage PT; Yang J; Yeung M; Azzi J; Vanguri V; Chandraker A; Sharpe AH; Sayegh MH; Najafian N
    Am J Transplant; 2011 Apr; 11(4):832-40. PubMed ID: 21401869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-1 targeting can promote allograft survival.
    Ozkaynak E; Wang L; Goodearl A; McDonald K; Qin S; O'Keefe T; Duong T; Smith T; Gutierrez-Ramos JC; Rottman JB; Coyle AJ; Hancock WW
    J Immunol; 2002 Dec; 169(11):6546-53. PubMed ID: 12444166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies.
    Lenschow DJ; Zeng Y; Hathcock KS; Zuckerman LA; Freeman G; Thistlethwaite JR; Gray GS; Hodes RJ; Bluestone JA
    Transplantation; 1995 Nov; 60(10):1171-8. PubMed ID: 7482727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart, but not skin, allografts from donors lacking Flt3 ligand exhibit markedly prolonged survival time.
    Wang Z; Castellaneta A; De Creus A; Shufesky WJ; Morelli AE; Thomson AW
    J Immunol; 2004 May; 172(10):5924-30. PubMed ID: 15128773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
    D'Addio F; Ueno T; Clarkson M; Zhu B; Vergani A; Freeman GJ; Sayegh MH; Ansari MJ; Fiorina P; Habicht A
    PLoS One; 2013; 8(4):e60391. PubMed ID: 23593209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo function of immune inhibitory molecule B7-H4 in alloimmune responses.
    Yamaura K; Watanabe T; Boenisch O; Yeung M; Yang S; Magee CN; Padera R; Datta S; Schatton T; Kamimura Y; Azuma M; Najafian N
    Am J Transplant; 2010 Oct; 10(10):2355-62. PubMed ID: 21143433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts.
    Mandelbrot DA; Furukawa Y; McAdam AJ; Alexander SI; Libby P; Mitchell RN; Sharpe AH
    J Immunol; 1999 Oct; 163(7):3753-7. PubMed ID: 10490971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the B7 costimulatory pathway in allograft rejection.
    Pearson TC; Alexander DZ; Corbascio M; Hendrix R; Ritchie SC; Linsley PS; Faherty D; Larsen CP
    Transplantation; 1997 May; 63(10):1463-9. PubMed ID: 9175811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.